A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

PHASE2CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

May 3, 2021

Study Completion Date

May 17, 2021

Conditions
GoutHyperuricemia
Interventions
DRUG

LC350189 formulated capsule

Xanthine Oxidase Inhibitor

DRUG

Placebo

Matching placebo

Trial Locations (34)

16635

Altoona Center For Clinical Research, Duncansville

23219

Dominion Medical Associates, Richmond

28226

OnSite Clinical Solutions, Charlotte

28277

OnSite Clinical Solutions, Charlotte

29621

Synexus Clinical Research, Anderson

31904

IACT Health, Columbus

32751

Meridien Research, Maitland

33176

Miami Dade Medical Research Institute, Miami

33458

Health Awareness Inc, Jupiter

33607

Clinical Research Trials of Florida, Inc, Tampa

33613

Avita Clinical Trials, Tampa

33709

Meridien Research, St. Petersburg

35211

Synexus Clinical Research, Birmingham

38654

Olive Branch Family Medical Cente, Olive Branch

43212

Synexus Clinical Research, Columbus

44130

Paramount Medical Research and Consulting, Middleburg Heights

44311

Synexus Clinical Research, Akron

45236

Synexus Clinical Research, Cincinnati

55423

Synexus Clinical Research, Richfield

60602

Synexus Clinical Research, Chicago

63141

Synexus Clinical Research, St Louis

68114

Quality Clinical Research, Omaha

68144

Synexus Clinical Research, Omaha

72211

Preferred Research Partner, Little Rock

75234

Synexus Clinical Research, Dallas

77450

Discovery MM Services Incorporated, Houston

78229

Synexus Clinical Research, San Antonio

78704

Avant Research Associates, Austin

84088

Advanced Clinical Research, West Jordan

84123

Synexus Clinical Research, Salt Lake City

85206

Synexus Clinical Research, Mesa

85224

Synexus Clinical Research, Chandler

85712

Synexus Clinical Research, Tucson

89052

Synexus Clinical Research, Henderson

Sponsors

Lead Sponsor

All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT03934099 - A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia | Biotech Hunter | Biotech Hunter